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Health care interventions are intended to
benefit patients, but they can also cause
harm. The complex combination of processes,
technologies and human interactions that
constitutes the modern health care delivery
system can bring significant benefits.
However, it also involves an inevitable risk of
patient harm that can – and too often does –
result in actual harm. A weak safety and
quality culture, flawed processes of care 
and disinterested leadership teams weaken
the ability of health care systems and
organizations to ensure the provision of safe
health care. Every year, a significant number
of patients are harmed or die because of
unsafe health care, resulting in a high public
health burden worldwide. 
Most of this harm is preventable. Adverse
events are now estimated to be the 14th leading
cause of morbidity and mortality in the world,
putting patient harm in the same league as
tuberculosis and malaria (1). The most important
challenge in the field of patient safety (see
Annex 1) is how to prevent harm, particularly
avoidable harm, to patients during their care.
Patient safety is one of the most important
components of health care delivery which is
essential to achieve universal health coverage
(UHC), and moving towards the UN Sustainable
Development Goals (SDGs). Extending health
care coverage must mean extending safe care,
as unsafe care increase costs, reduces
efficiency, and directly compromises health
outcomes and patient perceptions. It is
estimated that over half of all medicines are
Preface
prescribed, dispensed or sold inappropriately,
with many of these leading to preventable harm
(2). Given that medicines are the most common
therapeutic intervention, ensuring safe
medication use and having the processes in
place to improve medication safety (see Annex
1) should be considered of central importance
to countries working towards achieving UHC.
The Global Patient Safety Challenges of the
World Health Organization (WHO) shine a light
on a particular patient safety issue that poses a
significant risk to health. Front-line interventions
are then developed and, through partnership
with Member States, are disseminated and
implemented in countries. Each Challenge has
so far focused on an area that represents a
major and significant risk to patient health and
safety (see Annex 1). In 2005, the Organization,
working in partnership with the (then) World
Alliance for Patient Safety, launched the first
Global Patient Safety Challenge: Clean Care Is
Safer Care (3), followed a few years later by the
second Challenge: Safe Surgery Saves Lives
(4). Both Challenges aimed to gain worldwide
commitment and spark action to reduce health
care-associated infection and the risks
associated with surgery, respectively.
Recognizing the scale of avoidable harm 
linked with unsafe medication practices and
medication errors, WHO launched its third
Global Patient Safety Challenge: Medication
Without Harm in March 2017, with the goal 
of reducing severe, avoidable medication-
related harm by 50% over the next five years,
globally (5).
6 MEDICATION SAFETY IN HIGH-RISK SITUATIONS
Medication error: case scenario
Mrs Poly, a 65-year-old woman, came to the outpatient clinic complaining of abdominal pain and
dark stools. She had a heart attack five years ago. At her previous visit three weeks ago she was
complaining of muscle pain, which she developed while working on her farm. She was given a
non-steroidal anti-inflammatory drug (NSAID), diclofenac. Her other medications included aspirin,
and three medicines for her heart condition (simvastatin, a medicine to reduce her serum
cholesterol; enalapril, an angiotensin-converting enzyme (ACE) inhibitor; and atenolol, a beta
blocker). She was admitted to hospital as she developed symptoms of blood loss (such as
fatigue and dark stools). She was provisionally diagnosed as having a bleeding peptic ulcer due
to her NSAID, and her doctor discontinued diclofenac and prescribed omeprazole, a proton
pump inhibitor. Following her discharge, her son collected her prescribed medicines from the
pharmacy. Among the medicines, he noticed that omeprazole had been started and that all her
previous medicines had been dispensed, including the NSAID. As his mother was slightly
confused and could not remember exactly what the doctor had said, the son advised his mother
that she should take all the medications that had been supplied. After a week, her abdominal
pain continued and her son took her to the hospital. The clinic confirmed that the NSAID, which
should have been discontinued (deprescribed), had been continued by mistake. This time Mrs
Poly was given a medication list when she left the hospital which included all the medications
she needed to take and was advised about which medications had been discontinued and why.
This Challenge follows the same philosophy as
the previous Challenges, namely that errors are
not inevitable, but are very often provoked by
weak health systems, and so the challenge is to
reduce their frequency and impact by tackling
some of the inherent weaknesses in the system.
As part of the Challenge, WHO has asked
countries and key stakeholders to prioritize
three areas for strong commitment, early action
and effective management to protect patients
from harm while maximizing the benefit from
medication, namely:
• medication safety in high-risk situations
• medication safety in polypharmacy 
• medication safety in transitions of care.
Consider the following case scenario
describing a medication error (see Annex 1)
involving these three areas.
In this scenario the key steps that should have
been followed to ensure medication safety 
in the inpatient setting include:
1. Appropriate prescribing and risk
assessment
Medication safety should start with appropriate
prescribing and a thorough risk–benefit
analysis of each medicine is often the first step.
In this case scenario, prophylactic aspirin 
and NSAID without a gastroprotective agent 
left Mrs Poly at an increased risk of
gastrointestinal bleeding. NSAIDs can also
increase the risk of cardiovascular events,
which is of particular concern, as she had had 
a myocardial infarction (heart attack) five years
ago. This is a good example of a high-risk
situation requiring health care professionals 
to prescribe responsibly after analysing 
the risks and benefits.
2. Medication review
A comprehensive medication review (see
Annex 1) is a multidisciplinary activity whereby
the risks and benefits of each medicine are
considered with the patient and decisions
made about future therapy. It optimizes the use
of medicines for each individual patient.
Multiple morbidities usually require treatment
with multiple medications, a situation described
as polypharmacy (see Annex 1). Polypharmacy
can put the patient at risk of adverse drug
events (see Annex 1) and drug interactions
when not used appropriately. In this case, 
there should have been a review of
medications, particularly as Mrs Poly was
prescribed aspirin and diclofenac together. 
The haemodynamic changes following blood
loss should have also prompted temporary
stopping the ACE inhibitor before restarting once
the episode of blood loss has been resolved.
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The events leading to the error in this scenario and how these could have been prevented are
reflected in Figure 1, and the text below.






















3. Dispensing, preparation and
administration
This is a high-risk situation as the medication
(diclofenac) has the potential to cause harm.
However, this medication was continued after
discharge when the patient transitioned from
hospital to home. Dispensing this medicine and its
administration caused serious harm to Mrs Poly.
Dispensing this medicine and its administration
caused significant harm to Mrs Poly.
4. Communication and patient engagement
Proper communication between health care
providers and patients, and amongst health
care providers, is important in preventing
errors. When Mrs Poly was severely ill due to
gastric bleeding, the NSAID was discontinued.
However, the decision to discontinue the
medicine was not adequately communicated
either to the other health care professionals
(including the nurse or the pharmacist) or to
Mrs Poly. Initial presenting symptoms due to
adverse effects could have been identified
earlier if she had been warned about the risks.
5. Medication reconciliation at care
transitions
Medication reconciliation is the formal process
in which health care professionals partner 
with patients to ensure accurate and complete
medication information transfer at interfaces 
of care. Diclofenac, the NSAID that can cause
gastrointestinal bleeding and increase the risk
of cardiotoxicity and had led to this hospital
admission, was discontinued, and this
information should have been communicated 
at the time of discharge (in the form of a
medication list or patient-held medication
record). This would have helped her and her
caregivers in determining what the newly added
and discontinued medications needed to be.
Medication-related harm is harm caused to 
a patient due to failure in any of the various
steps of the medication use process or due 
to adverse drug reactions (see Annex 1 for
glossary). The relationship and overlap between
medication errors and adverse drug events 
is shown in Figure 2.
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Figure 2. Relationship between medication errors and adverse drug events 
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WHO is presenting a set of three technical
reports – Medication safety in high-risk
situations, Medication safety in polypharmacy,
and Medication safety in transitions of care – 
to facilitate early priority actions and planning
by countries and key stakeholders to address
each of these areas. The technical reports are
intended for all interested parties, particularly 
to inform national health policy-makers and
encourage appropriate action by ministries 
of health, health care administrators and
regulators, organizations, professionals,
patients, families and caregivers, and all who
aim to improve health care and patient safety.
This report – Medication safety in high-risk
situations – outlines the problem, current
situation and key strategies to reduce
medication-related harm in high-risk situations.
It should be considered along with the
companion technical reports on Medication
safety in polypharmacy and Medication safety
in transitions of care.
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High-risk situations are important because they
are more often associated with significant harm
due to unsafe medication practices or
medication errors. There are three main factors
contributing to high-risk situations: medication,
provider and patient, and systems factors (work
environment).
• Medication factors include the use of high-
risk (high-alert) medications, often medicines
with a low therapeutic index (a low ratio of
the maximally tolerated dose of a medication
to the minimal curative or effective dose). 
The development of local high-risk (high-alert)
medication lists that are regularly updated
help health care professionals focus on
particular risks in their own workplace. 
This report seeks to highlight some of the
medications which have been identified
globally as being high-risk (high-alert).
However, such lists need to be developed
locally to reflect the medications most
commonly associated with medication error
and adverse drug events in different
countries and health care settings. Merely
creating a high-risk (high-alert) medication 
list is of little use without associated risk
reduction strategies.
• Provider and patient factors may be related
to the health care professional providing
patient care or the patient being treated. 
Poor prescribing practices by health care
professionals include overprescribing,
underprescribing and misprescribing.
However, errors may occur at any stage 
of the medication process, including
dispensing and administration.
• Systems factors (work environment) include
the setting (such as hospitals) and high-risk
situations within those settings (e.g. risks
associated with perioperative or neonatal
care).
Medication errors are often caused by 
a combination of medication, provider and
patient, and systems factors; therefore, 
a range of sustainable strategies of proven
efficacy should be developed and implemented
in conjunction. 
These strategies form part of a systems
approach to reduce the risk of medication
errors, supported by a strong safety and
reporting culture, alongside education and
feedback.
Each country participating in the third WHO
Global Patient Safety Challenge: Medication
Without Harm needs to clearly define its own
objectives for improving medication safety 
by convening a group of experts, including 
for instance physicians, pharmacists, patient
representatives, regulators and health system
leaders; to select a small number of high-risk
(high-alert) medications and high-risk situations
for action that are applicable to their situation




11MEDICATION SAFETY IN HIGH-RISK SITUATIONS
Introduction
High-risk situations, in the context of medication
safety, relate to those circumstances which are
associated with a significant risk of medication-
related harm. The inherent risks of certain
medications, unsafe medication use processes
and difficulty in complying with safe medication
practices in certain clinical scenarios (such 
as in the case of emergencies) are just some
examples of high-risk situations. These may
result in an adverse drug reaction (ADR) or a
medication error, which are often preventable.
High-risk situations warrant special
mechanisms to prevent medication errors, 
and when they do occur, should include 
means of identifying and intercepting them
before they result in harm to the patient.
Some high-risk situations may require
improvements in various steps of the
medication use process. Situations arising 
from look-alike, sound-alike (LASA) naming,
packaging and labelling of some medications,
could be prevented by ensuring that these 
are checked thoroughly during prescription,
transcription, procurement, storage and
dispensing. Medications with an increased 
risk of harm, such as concentrated electrolyte
solutions, can be stored in a controlled
environment to prevent the inadvertent
administration of undiluted solutions.
It has been suggested that there are three
broad factors that influence medication safety
in high-risk situations (7). These are:
• medication factors
• provider and patient factors
• systems factors.
Unsafe medication practices and medication
errors may be triggered by one or more of
these factors acting alone or in combination,
increasing the risk of harm to patients. The
following sections consider each of these
factors in turn.
1
High-risk (high-alert) medications are drugs
that bear a heightened risk of causing
significant patient harm when they are used 
in error. Although mistakes may or may not
be more common with these medications,
the consequences of an error are clearly
more devastating to patients (see Annex 1).
Studies have shown that there is a burden 
of harm associated with ADRs. In one study, 
it was estimated that ADRs are related to 6.5%
of hospital admissions (8). In practice many
medication errors may not result in harm and
although every medicine has risks during use,
medication-related harm can be reduced with
appropriate prescribing, responsible use, and
by implementing strategies that minimize risks.
Medications associated with a high risk of
ADRs are traditionally classified under two
categories: (a) those with a high risk of type A
(for “augmented”) reactions, normally a dose-
related “augmentation” of the known
pharmacological effects of the medication; and
(b) those with a high risk of type B (for “bizarre”)
reactions, sometimes termed “idiosyncratic”,
for which the effect is often unpredictable (and
sometimes allergic in nature) and not related 
to the known pharmacological properties 
of the medication. It has been proposed that
there could be more classification schemes 
and categories for classifying ADRs (9). Digoxin
toxicity would be classified as a type A reaction
while anaphylaxis (see Annex 1) caused by 
the penicillin group of antibiotics is an example
of a type B reaction (10). However, some
medications may be associated with a
significant risk of both type A and type B
reactions (e.g. the antiarrhythmic agent,
amiodarone). 
Type A reactions are common, often
predictable and are generally associated with
medications which have a low therapeutic
index (the ratio of the maximally tolerated dose
of a medicine to the minimal curative or
effective dose), which is associated with a
steep dose–response curve (9, 10). This means
that even small increases in the concentration
of the medication at its site of action (e.g. 
due to a drug interaction, medication error 
or concomitant clinical condition) may cause 
a significant increase in its effect, sometimes
resulting in harm. Thus, even doses of the
medication within the recommended range 
may produce ADRs in some individuals, due 
to variation in their response to medicines 
and as the safe dose range may be narrow.
Type B reactions are less common than type A
reactions and have a higher mortality rate.
Examples of type B reactions include skin
rashes (sometimes severe) which can occur
with certain antibiotics and other immunological
reactions. Some of the serious ADRs
associated with type B reactions are severe
anaphylaxis and malignant hyperthermia (9, 10).
In the absence of sensitive and specific
biomarkers, such reactions are often difficult to
predict, so prevention of future type B reactions
usually requires obtaining a comprehensive
medication and medication-allergy history, 
and the establishment of systems to prevent
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Medication factors2
subsequent inadvertent re-administration of 
the suspected medication. Since predicting
these ADRs is difficult, the objective could be
to have systems in place to recognize the
reactions and manage in a timely, proper
manner when required.
2.1 Medications frequently
classified as high-risk (high-alert)
Many medicines may have a high risk of harm
when used in error or taken inappropriately. 
The specific medications contained in lists 
of high-risk (high-alert) medications may differ
between countries because of variation in
preferences of specific agents within a class, 
as well as variations in care settings and
disease epidemiology. Nevertheless, there is
generally good concordance between the
classes of medications in reports from several
countries, and a selected list is shown in Table
1. It has been observed that these therapeutic
groups can be easily recalled using the
mnemonic “A PINCH” (which is not
representing the order of severity of potential
harm they can cause), first proposed by the
New South Wales Clinical Excellence
Commission (11). Many of the therapeutic
groups listed in A PINCH have been identified
as high-risk (high-alert) by various entities
globally (12–18). It is important to note that
while Table 1 includes examples of the
medications frequently classified as high-risk
(high-alert), there are several other medications
which have been implicated less frequently. 
In addition, some authors have separately
identified high-risk (high-alert) medications 
most likely to be associated with harm in acute
care settings, community settings and long-
term care settings (14).
13MEDICATION SAFETY IN HIGH-RISK SITUATIONS
High risk medicine group Examples of medicines
A: Anti-infective Amphotericin
Aminoglycosides
P: Potassium and other electrolytes Injections of potassium, magnesium, calcium,
hypertonic sodium chloride
I: Insulin All insulins
N: Narcotics (opioids) and other sedatives Hydromorphone, oxycodone, morphine 
Fentanyl, alfentanil, remifentanil and analgesic
patches
Benzodiazepines, for example, diazepam, midazolam
Thiopentone, propofol and other short term
anaesthetics




H: Heparin and anticoagulants Warfarin
Enoxaparin
Rivaroxaban, dabigatran, apixaban
Other High-risk medicines identified at local health
district/facility/unit level which do not fit the above
categories
Table 1. Some high-risk (high-alert) medications associated with harm when used in error
Source: Reproduced, with the permission of the publisher, from State of New South Wales (NSW Ministry 
of Health) (11).
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A recent systematic review of the prevalence
and incidence of prescribing errors with 
high-risk (high-alert) medications in hospitals
included nine studies published between 2008
and 2014 (19). It showed that the prevalence 
of prescribing errors was highly variable,
perhaps because of different definitions of 
both prescribing errors and high-risk (high-alert)
medications, and could be extremely high
(ranging from 0.24 to 89.6 errors per 100
prescriptions). It is of concern that the three
highest prevalence rates in this systematic
review were observed in studies in children,
with a child’s weight not recorded or incorrectly
recorded being the most common error. The
commonest type of prescribing error identified
by the systematic review was dosage error.
Other common prescribing errors of high-risk
(high-alert) medications included incorrect 
date of prescription and omissions of required
medications. It was also noted that despite 
safe prescribing policies being in place, they
were often not strictly followed. Thus, it is
evident that high-risk (high-alert) medications
pose a major clinical challenge for prescribers.
It is important to highlight that errors can 
also occur in any of the other steps of 
the medication use process (e.g. storage,
preparation, dispensing, administration or
monitoring). These will be discussed later 
in this report.
Adverse drug events during hospitalization 
in Dutch hospitals demonstrated no visible
improvements in preventable adverse events
related to medication over the four years after 
a national programme Prevent Harm, Work
Safely was launched in 2008, with the aim of
reducing the number of preventable adverse
events by 50%. The intervention targeted two
aspects related to medication; medication
reconciliation at hospital admission and
discharge, and high-risk (high-alert) medication
(20). A Dutch study by Damen et al. found 
that adverse drug events related to chemo-
therapeutic agents and anticoagulants were 
the commonest. In this study, anticoagulant-
related events accounted for a substantial
proportion of preventable adverse drug events
(21). However, management of anticoagulation
is complex and requires good coordination 
and communication within the health care team
for safe and effective medication practice.
A recent review identified narcotic agents
(particularly opioids) as the high-risk (high-alert)
medications most often associated with
prescribing errors in the hospital setting (19).
Another recent survey of adverse drug events
during hospitalization cited chemotherapeutic
and anticoagulants as the two main medication
types responsible for medication-related
adverse events (21). Thus, in any intervention
plan, it would be appropriate to focus attention
on those high-risk (high-alert) medications that
are associated with the greatest likelihood of
producing serious harm in specified settings.
Most of these interventions do not require
sophisticated monitoring facilities and could be
widely adopted globally to minimize risk
associated with the administration of high-risk
(high-alert) medications. 
The medication safety information and
interventions given below are not exhaustive
but have been suggested by different
international bodies to minimize medication-
related harm from high-risk (high-alert)
medications.  
Anti-infective agents
Aminoglycosides (11) (e.g. amikacin,
gentamicin, streptomycin and tobramycin) and
the glycopeptide antibiotic, vancomycin (17),
may cause damage to hearing or the kidneys in
a dose-related, type A adverse drug reaction.
Individuals at particular risk are those with pre-
existing renal impairment, older persons, obese
individuals, patients with cystic fibrosis,
neonates and children, particularly when high
doses are administered. Since the major route
of excretion of these medications is by filtration
through the kidney, any nephrotoxicity caused
by the medications can further reduce their
renal clearance, resulting in a vicious cycle of
increasing renal damage and reduced excretion
of the offending agent (22).
Rapid intravenous infusion of vancomycin
increases the risk of anaphylactic-like reactions,
so particular care should be exercised during
intravenous infusion, especially during any
loading infusion (23).
Amphotericin B is used in the treatment of
severe fungal infections and is available in
several formulations. Lipid-based forms of the
medication appear to have less severe toxicity,
but the conventional form of the medication
may be inadvertently substituted at an
inappropriate dose, risking possible severe
cardiotoxicity, including cardiorespiratory 
arrest (24, 25).
Potassium and other salts or electrolytes 
for intravenous injection
Potassium is a vital component for normal
cellular function, and deficiency of potassium 
in the blood (hypokalaemia) may need to be
corrected rapidly by administering intravenous
potassium (usually the chloride salt in dilute
form) to avoid serious sequelae, including
cardiac arrest. It has been observed that
concentrated potassium chloride, in place 
of the diluted solution, is occasionally
administered in error, sometimes resulting 
in fatal outcomes due to severe hyperkalaemia
(12, 26). There have been many incidents
where health care professionals have mistaken
potassium chloride concentrate solution for
sodium chloride (normal saline) solution when
reconstituting a medication for injection, or in
other cases, intravenous infusions of potassium
chloride have been prepared incorrectly (27, 28).
Harm can also occur as a result of
administration of other electrolytes, including
potassium phosphate, magnesium and calcium
salts and hypertonic sodium chloride (11, 16,
18). Administration errors of hypertonic sodium
chloride can have fatal outcomes (26).
Insulins 
Various publications identify insulin as a 
high-risk (high-alert) medication (11–18). 
The complexity of dosing, variety of available
products and pharmacology of the medicine, 
all contribute to the potential for error and
insulin-related harm (15). Two common errors
that have been identified in association with
insulin administration are (a) use of non-insulin
syringes, which are marked in millilitres and not
in insulin units, to administer the dose; and (b)
use of abbreviations such as “U” or “IU” for
units, which when added to the prescription for
the intended dose may cause it to be misread
(e.g. “10U” misread as “100”) (29). The
introduction of new formulations (including
high-strength) requires prescribers to become
familiar with various preparations to avoid error.
Narcotics and sedatives
Narcotics and sedatives can cause significant
harm when used in error (11–18). Type A
reactions associated with opioid medications
(e.g. buprenorphine, diamorphine, dipipanone,
fentanyl, hydromorphone, meptazinol,
methadone, morphine, oxycodone,
papaveretum, tramadol and pethidine) include
nausea, vomiting, constipation and in severe
cases respiratory depression or respiratory
arrest which may result in death. The availability
of a wide range of alternative opioids (some
short-acting and others long-acting) make the
possibility of an error more likely, as health care
professionals may not be familiar with different
preparations. Health care professionals should
therefore check that the intended dose 
of the specific opioid is safe for the individual
receiving it, and an awareness of the previous
opioid dose is vital in ensuring the safe use 
of these medications (30).
Some opioid medications are also administered
transdermally (across the skin), especially for
cancer pain, and patients or caregivers should
be educated about how to use them correctly.
Opioids and sedatives are widely used in
paediatric anaesthesia, and a recent study
found that these agents were the two most
common causes of medication errors. Over
80% of reported medication errors in this study,
reached the patient and over half of these
errors caused patient harm (31).
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Chemotherapeutic and immunosuppressive
agents 
The increasing availability of a wide range 
of orally active anticancer medications, allied 
to their generally low therapeutic indices,
means that errors in the dose, frequency, or
duration of treatment can be a cause of harm.
The United Kingdom National Patient Safety
Agency has advised that the prescribing and
use of oral cytotoxic medications should be
carried out to the same standard as parenteral
anticancer therapy and should be monitored 
in the same way (32).
The alkylating agent etoposide is available in
two different intravenous formulations, the
etoposide base and the etoposide phosphate
salt, with 100 milligrams of the etoposide base
being equivalent to 113.6 milligrams of
etoposide phosphate. This can lead to dosing
errors if these differences are not taken into
account (33).
Vincristine is used to treat certain leukaemia,
lymphomas, and some solid tumours, such as
breast and lung cancer. Vincristine injections
are intended for intravenous administration 
only and inadvertent intrathecal administration
has caused severe ascending radiculomyelo-
encephalopathy, which is almost always fatal (11).
Although the folic acid antagonist methotrexate
is used as an anticancer agent, it is also 
used in the treatment of rheumatoid arthritis
and other autoimmune conditions due its
immunosuppressive properties. In the
treatment of autoimmune conditions, it is often
administered as a weekly rather than daily 
dose which can lead to errors and significant
harm (11, 12, 13, 34). Errors in prescription or
dispensing of excessive doses of methotrexate
have resulted in bone marrow suppression,
pulmonary complications and, in some cases,
even death.
Heparins and oral anticoagulants
Anticoagulants are high-risk (high-alert)
medications (11–18), widely used both in
inpatient and outpatient settings.
Unfractionated heparin (UFH) is still used
parenterally in high-risk situations, either by
intravenous infusion or subcutaneously, with
monitoring of the blood using the activated
partial thromboplastin time (aPTT). It has been
shown that there is a non-linear relationship
between the dose of UFH infused and the
aPTT. This means that disproportionate
adjustments in dose are required depending on
the aPTT if underdosing or overdosing is to be
avoided. It has been observed that overdosing
is associated with an increased risk of
haemorrhage (35). Heparin was also shown to
be the most common medication associated
with prescription errors in a Brazilian study (36).
In many clinical circumstances, UFH has been
replaced by low molecular weight heparins
(LMWH), which are typically administered
subcutaneously (35). They are predominantly
excreted unchanged in the urine and the safe
and effective dose is determined by the
patient’s weight and renal function.
Underdosing risks inefficacy while overdosing
may increase the risk of haemorrhage (37).
Orally active vitamin K antagonists, including
warfarin, phenindione, acenocoumarol
(nicoumalone) and phenprocoumon, are widely
used throughout the world in the treatment 
and prevention of thrombosis, particularly 
in the prevention of thromboembolic stroke 
in individuals with (valvular and non-valvular)
atrial fibrillation. The main type A reaction 
of all of these agents is haemorrhage. Due to
the low therapeutic index of these agents, 
and the wide inter-individual pharmacokinetic
and pharmacodynamic variability caused 
by genetic and environmental influences, these
medications should be monitored throughout
treatment using the international normalized
ratio (INR) (38).
A study in the community revealed that
monitoring errors (when a prescribed
medication is not monitored in the way that
would be considered acceptable in routine
general practice) involved warfarin in nine out 
of 11 severe medication errors. The most
16 MEDICATION SAFETY IN HIGH-RISK SITUATIONS
common error was failure to monitor or
document the INR for a considerable period
(sometimes for more than two years) in patients
receiving long-term anticoagulant therapy (39).
In the United Kingdom, warfarin (which still
accounts for almost all of the use of vitamin 
K antagonists) was reported 10 years ago 
as one of the medications most commonly
associated with medication errors leading to
severe harm including death (38). The same
report noted that in secondary care, it was one
of the 10 medications most frequently related 
to dispensing errors. Bleeding in association
with oral anticoagulants is also one of the 
most frequent causes of hospital admission,
particularly in older people (40). This is probably
in part related to their increased sensitivity 
to warfarin, and increased frequency of
concomitant conditions leading to unstable
anticoagulation (e.g. heart failure and drug
interactions). The risk of bleeding in association
with anticoagulant use is highest early in
therapy during anticoagulant induction and
stabilization as the appropriate dose for a
particular individual is often not known early 
in the course of treatment. In addition, the low
therapeutic index means that even small
increases in the dose may cause a significantly
increased risk, particularly if there is a potential
underlying bleeding site not yet identified.
Newer oral anticoagulants (NOACs), also
known as direct-acting oral anticoagulants
(DOACs), including apixaban, dabigatran,
edoxaban and rivaroxaban, are agents acting
directly on clotting factor II or X. The main type
A reaction is haemorrhage. In a recent study 
in the United States of America, almost 18% 
of all oral anticoagulant-related medication
errors involved NOACs. The commonest error
associated with all oral anticoagulant therapy
was the omission of a dose (41).
2.2 Other medications occassionally
considered as being high-risk 
(high-alert)
Non-steroidal anti-inflammatory drugs used 
for pain associated with inflammation can be
high-risk (high-alert) medications in certain
circumstances. Type A reactions include
gastrointestinal effects (e.g. ulceration) 
and cardiotoxicity (including exacerbation 
of heart failure, worsening of hypertension 
and myocardial infarction due to increased
thrombotic risk). NSAIDs may also rarely
precipitate renal failure (42). Those at particular
risk of such events are patients already at higher
risk of gastrointestinal, renal or cardiovascular
morbidity (including older persons).
Paracetamol (acetaminophen) is one of the
most widely used over-the-counter medicines
and has been responsible for a high rate of
medication errors in children, including several
instances of dose-related liver failure (43).
Lithium salts are used in the treatment of 
a range of psychiatric disorders, including 
the treatment and prevention of mania, bipolar
disorder and recurrent depression. They 
have a narrow therapeutic index, so should
ideally only be given when serum lithium
concentrations can be regularly monitored (44).
Type A reactions of lithium include
gastrointestinal and central nervous system
disturbances, and cardiac conduction
disturbances. Lithium is largely eliminated
unchanged by the kidney, and has the potential
to interfere with kidney and thyroid function, 
so these functions should be monitored prior 
to starting treatment, and regularly thereafter.
Special consideration is required for women of
childbearing age, so a pregnancy test should
also be performed if relevant (44, 45).
Allergies to medications can cause high-risk
situations when used in error, while
medications causing allergic reactions are not
necessary considered as high-risk (high-alert)
medications. One example of this is allergy to
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antibiotics with beta-lactams (especially
penicillins) predominating. The most severe
allergic reaction to penicillin, anaphylaxis, 
was estimated to cause 500 –1000 fatalities 
in the United States of America each year (46).
Unfortunately, individuals who have previously
experienced a rapid-onset allergic reaction in
relation to a medicine may be given the same
agent again, sometimes with fatal outcome.
Several other groups of medications (e.g.
diuretics, cardiac glycosides and neuroleptics)
may be considered to be high-risk (high-alert),
particularly in certain patient groups. Thus,
these agents are included in the Screening 
Tool of Older Person’s Prescriptions (STOPP)
criteria (47).




Standardization and systematization of
processes and documentation (including naming,
packaging and labelling) are important in
reducing harm from high-risk (high-alert)
medications (48, 49). To support the
implementation of Australia’s national medication
safety standard, the Australian Commission 
on Safety and Quality in Health Care developed 
a National medication management plan,
National recommendations for user-applied
labelling of injectable medications, fluids and
lines, and a National tall man lettering list (50).
The tall man lettering approach is discussed 
in further detail by U and Cohen (51). 
Prescribing errors decreased upon introduction
of a standardized inpatient medication
prescription chart in Queensland (52), and then
across Australia (53). The Australian National
Inpatient Medication Chart and support
materials are accompanied by standardized
national terminology, abbreviations and symbols
to be used in the prescribing and administering
of medications in Australian hospitals (54).
A similar approach was adopted in
the development of a national inpatient
prescription chart in Wales in 2004 (55) that
has now been endorsed by the Royal College
of Physicians as an example of good practice
(56). Several standards for the design of
paper-based hospital inpatient prescription
charts outlined by the Academy of Medical
Royal Colleges will also be applicable to
electronic prescribing when they become
available in a particular region, state or
country (57). In conjunction with chart
standardization, standards for prescribing 
can be agreed at national level (58).
A study by Rozich et al. found that when
patterns of care are widely divergent, clinical
outcomes may be suboptimal and safety 
may be jeopardized (59). Standardization 
of processes can reduce the risk of error. 
The authors demonstrated that standardization
of a sliding scale protocol for insulin was
associated with better outcomes in hospital
inpatients. Donaldson found that weaknesses
or deficiencies in communication, safety
culture, operational practices, protocols 
and training, and packaging and design of
medications and equipment, all contributed
to episodes when vincristine sulphate was
inadvertently administered intrathecally 
with fatal consequences (60). This particular
problem has since been successfully
addressed by standardization of practices,
indicating that it is possible to eliminate 
certain medication errors by using effective
strategies.
Assessing safety risks of products
The National Patient Safety Agency of the
United Kingdom has recommended that all
health organizations develop a purchasing 
for safety policy for medication safety (61).
Products can be assessed using a risk score
approach such as the medication error
potential assessment (MEPA), which reflects 
a product’s suitability for use based upon 
a wide range of factors (e.g. clarity of labelling,
packaging, and availability of patient
information). A pharmaceutical quality risk
assessment tool has been made available 
for this purpose (62).
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There is some evidence that barcoding 
of medications might reduce medication 
and administration errors (63), and an
implementation plan using the GS1 global
standard is available (64).
Medication errors and adverse drug reactions
may also be associated with substandard and
falsified medical products. Further information
is available from WHO (65).
Reporting and learning systems and
pharmacovigilance centres
A strong safety culture is one where errors 
are anticipated and watched for, where risks
are proactively assessed and managed, and
where health care professionals feel
comfortable and confident to discuss and
report errors and near misses (see Annex 1)
and learn from them. Details of two initiatives 
to support reporting and learning – the WHO
Minimal Information Model for Patient Safety
and the Conceptual Framework for the
International Classification for Patient Safety –
can be found on the WHO website (66). Tools
are available to assess, develop and improve
organizational safety culture (67–69).
Although the primary role of regional and
national pharmacovigilance centres (see 
Annex 1) is to optimize the reporting and
detection of suspected adverse drug reactions,
it has been shown that they can also detect,
identify, analyse, and classify medication errors
and carry out root cause analysis to investigate
causality (70).
Patient Safety Reporting and Learning System
have been implemented at a national level 
in Spain, and England and Wales (71, 72). 
The reporting system may encompass all types
of incidents related to patient safety and be
designed to respond to the context unique
needs identified by the stakeholders (71).
Use of multiple strategies
Due to the complexity of systems in health, 
the Institute for Safe Medication Practices 
has highlighted that a single strategy for
addressing the risks associated with each 
high-risk (high-alert) medication in the acute
care setting is rarely sufficient (73).
The following measures may therefore be
considered:
• Several risk reduction strategies may be used
together.
• Strategies may be chosen that influence as
many steps of the medication management
system as possible.
• “High-leverage” risk reduction strategies,
such as forcing functions (see Annex 1) and
standardization, may be bundled together
with “low-leverage” strategies, such as staff
education and passive information
dissemination (Table 2).
• Strategies that have been implemented
successfully, proven effective and
recommended by experts, should be used.
• The strategies that are chosen should be
sustainable.
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2.4 Potential actions to reduce
medication-related harm due to
medication factors in high-risk
situations
The following guidance is not comprehensive,
but constitutes advice given by a range of
authorities worldwide. They may be adapted 
to suit local contexts depending on their
applicability. Valuable resources for further
information are listed in Annex 2.
Anti-infective agents
Aminoglycosides (74)
• Aminoglycoside doses (e.g. gentamicin)
should be calculated taking into account 
the patient’s weight and renal function 
(e.g. using a nomogram). Adjustments 
can then be made according to serum
gentamicin concentrations.
Vancomycin (75)
• Monographs to improve the safe use of
intravenous vancomycin and other commonly
used antibiotics are available at the reference
website, providing information for home and
community care, and how various antibiotics
should be prepared, stored and administered
Amphotericin B (24, 76)
• Potential local interventions include
segregating storage areas in the fridge 
for different formulations of amphotericin
(lipid-based and non-lipid based), and use 
of cautionary labels or warning signs 
to remind staff about the differences.
Key strategies Description
Failure mode effects analysis Proactively identify risks and how they can be minimized
(FMEA) and self-assessments
Error-proof designing Build in safeguards to prevent or respond to failure
(forcing functions and fail-safes)
Limit access or use Use constraints (e.g. restriction of access or requirement 
for special conditions or authorization)
Maximize access to information Use active means to provide necessary information when 
critical tasks are being performed
Constraints and barriers Use special equipment or work environment conditions 
to prevent hazard from reaching patient
Standardize Create clinically sound, uniform models of care or products 
to reduce variation and complexity
Simplify Reduce number of steps in the process of handoffs
(handovers) without eliminating crucial redundancies
Centralize error-prone processes Transfer to external site to reduce distraction of staff with
expertise, with appropriate quality control checks
Preparation to respond to errors Have antidotes, reversal agents or remedial measures readily
available and ensure staff are appropriately trained to manage 
an identified error
Source: Adapted, with the permission of the publisher, from Institute for Safe Medication Practices (73).
Table 2. Key strategies for medication safety
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Potassium and other salts or electrolytes 
for intravenous injection (26, 28, 77, 78)
• In critical areas where high concentrations
and doses of potassium chloride are
necessary, a risk assessment should be
performed to determine whether it is
appropriate to keep the ampoules as a stock
item in the critical areas. If required as 
a stock item, a protocol for safe storage,
preparation and use should be developed.
• In the general ward, need for potassium
chloride ampoules (and other concentrated
potassium salts) should be assessed and
stock may be removed if not necessary.
Replacement with premixed solutions could
also be considered.
• The storage of potassium chloride ampoules
and premixed solutions should be assessed
periodically to ensure they are stored
separately and are readily identifiable from
preparations with similar packaging.
Insulins (79, 80)
• Abbreviations, unclear instructions and
ambiguous doses should be avoided. Insulin
syringes and well titrated doses should be
used. Moreover, prescribing by “brand name”
and device could reduce error.
• When storing insulin, consider physically
separating insulin from vaccines or LASA
products, or store vaccines in a separate
fridge if possible.
• Engagement of patients and caregivers is
strongly encouraged. They should be
educated to identify symptoms of
hyperglycemia and hypoglycemia, and
encouraged to take immediate corrective
measures or seek advice when needed.
Patients and caregivers should also be
empowered to seek clarification at any time
and to ensure there is a clear understanding
of their signs, symptoms and treatment,
insulin use in relation to meals and illness,
and the differences between the different
types of insulins.
Narcotics and sedatives (13, 81–84)
• The correct product in the correct dose
should be selected, particularly with
morphine and diamorphine as they carry an
increased risk of adverse events at high
doses.
• To minimize the risks in neonatal units, staff
should ensure that protocols relating to the
preparation and administration of intravenous
morphine for neonates are clear and easy to
follow. For example, steps may be outlined
separately in a checklist format. In addition,
the use of prefilled syringes from a central
intravenous additive service and smart
pumps could be considered.
• Guidance on counselling patients and
caregivers on the safe use of opioid patches
is available.
• Navigating opioids for chronic pain is a tool
that provides guidance on different opioid
options based on morphine equivalence to
compare the relative potency of these
different medications.
• Opioid pain medicines information for
patients and families provides guidance and
information for patients to consider when
prescribed an opioid medicine.
Chemotherapeutic and immunosuppressive
agents (32)
• Processes should be in place to avoid
administering the wrong medication, dose,
route, concentration, duration or frequency.
The prescribing and use of oral
chemotherapeutic medications should be
carried out to the same standard as
parenteral anticancer therapy and should be
monitored in the same way.
Heparins and oral anticoagulants
Unfractionated heparin (UFH) (35)
• All patients should have a baseline aPTT
performed before initiation of therapy.
• Platelet counts should also be measured just
before therapy with UFH, and regular
monitoring of platelet counts may be required
if UFH is administered for longer than four
days.
Low molecular weight heparin (LMWH)
(37, 85, 86)
• The weight of the patient is used to calculate
the treatment dose required of LMWH. The
medication chart (when in use) and clinical
record should have the weight of the patient
accurately recorded. At the beginning of
therapy, patients should be weighed and,
during treatment, where applicable.
• When prescribing treatment doses of LMWH,
renal function should be taken into account.
Initiation of the first dose should not be
delayed by renal function tests but every
effort should be made to base subsequent
dosing on these results.
• Dose calculation tools are available for
different LMWH products, specific clinical
indications and varying body weights.
• Rationalizing the variety of LMWH products
used within an organization has been used 
as a means to reduce errors.
Vitamin K antagonists (e.g. warfarin) (87)
• Prior to commencing anticoagulation, a risk
assessment should be undertaken and
documented, and repeated on an annual
basis.
• Prescribers should discuss the risks, benefits
and implications of long-term warfarin
treatment with newly diagnosed patients.
This discussion should be documented 
and decision aids used where possible.
• The baseline prothrombin time (or INR)
should be determined.
• The appropriate (rapid or slow) induction
should be used. This should reduce the
likelihood of ineffective or excessive
anticoagulation and some can also be used
to predict the likely long-term daily doses 
of warfarin.
• INR should be measured regularly,
particularly during the induction period.
• Computer dosing software could be used
when available.
• Anticoagulant treatment booklets may be
issued to all patients; these booklets could
include advice for patients on anticoagulant
treatment, an alert card to be carried 
by the patient at all times, and a section 
for recording INR results and dosage
information. 
• There should be reliable follow-up systems 
in primary care to ensure that patients on
warfarin are reviewed regularly and not lost 
to follow-up.
Newer oral anticoagulants /direct oral
anticoagulants (88)
• When prescribing a NOAC an in-depth
knowledge of its pharmacology and clinical
use is needed. Prior to prescribing,
conducting a risk–benefit assessment should
be considered. Careful patient selection 
and monitoring ensures the best outcomes.
• Before prescribing a NOAC creatinine
clearance should be calculated (e.g. using
the Cockcroft Gault equation and ideal body
weight) and documented.
• If renal function is impaired, excessive
anticoagulation and drug accumulation can
occur. Renal function should be monitored 
at least annually. Monitoring frequency may
be increased to every three or six months
due to declining renal function or
dehydration, and amongst older persons.
These factors should be communicated
through all transitions of care (see Annex 1)
to ensure proper monitoring.
• NOACs have fewer drug interactions than
warfarin; however, many clinically significant
interactions exist. Individual patient bleeding
risks should be considered and specialist
advice could be sought, as these are often
complex situations.
• Counselling of patients and caregivers could
include communicating the discharge
information from hospital care, promoting
regular and adequate follow-up and
explaining how to recognize and respond 
to bleeding, and to seek medical attention
immediately if bleeding is suspected.
Other medications
Non-steroidal anti-inflammatory drugs (42)
In the United Kingdom, the National Institute 
for Health and Care Excellence has proposed
the following options for local implementation
concerning NSAIDs:
• Review the appropriateness of NSAID
prescribing widely and on a routine basis,
especially in people who are at higher risk of
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gastrointestinal, renal and cardiovascular
morbidity and mortality (e.g. older people).
• If an NSAID is needed, use ibuprofen (1200
milligrams a day or less) or naproxen (1000
milligrams a day or less). Use the lowest
effective dose and the shortest duration of
treatment necessary to control symptoms.
• Consider co-prescribing proton pump
inhibitors with NSAIDs, especially when used
in those with risk of gastric bleeding or when
used for long-term treatment of osteoarthritis,
rheumatoid arthritis and lower back pain.
Paracetamol (acetaminophen) (43)
• To reduce dosing errors of paediatric liquid
paracetamol (acetaminophen), extra attention
should be paid to the dosing instructions, 
use of the correct measuring device,
concentration of the paracetamol preparation
to be administered, and whether or not
paracetamol is included as an ingredient in
other combination medication preparations.
Lithium (89)
• Patients prescribed lithium should be
monitored in accordance with local guidance.
• There should be reliable systems in place
such as an electronic alert, to ensure blood
test results are communicated between
laboratories and prescribers.
• At the start of lithium therapy and throughout
treatment, patients may be given a record
book to track serum lithium levels and other
relevant clinical tests, and appropriate,
continuing verbal and written information.
• Prescribers and pharmacists should check
that blood tests are monitored regularly 
and if it is safe to issue a repeat prescription
or dispense the prescribed lithium.
• Mechanisms to identify and deal with
medications that might adversely interact
with lithium therapy are very helpful.
Antibiotic allergy (56, 90–92)
• Information regarding previous adverse 
drug reactions should be elicited,
documented and considered prior to
prescribing, dispensing and administering 
a medication, including topical medications.
Documentation of allergy history should be 
in a location where it can easily be reviewed
by the prescriber (Figure 4).
• Advice on the diagnosis and treatment 
of antibiotic allergies is available, including
from the National Institute for Health and
Care Excellence and Australasian Society 
of Clinical Immunology and Allergy.








This section must usually be completed prior to administration of any medicine. 





Figure 4. Example of medication allergies and sensitivities section of a paper-based
inpatient prescription chart
Source: Reproduced, with the permission of the publisher, from Royal College of Physicians (56).
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Provider and patient factors3
Provider and patient factors influencing
medication safety can relate to either the 
health care professional providing care or 
to the patient being treated.
3.1 Health care professionals 
Even the most dedicated health care
professional is fallible and can make errors (93).
The act of prescribing, dispensing and
administering a medicine is complex, normally
involving several health care professionals, 
with the patient necessarily being a part of, 
and in the centre of, what should be a
“prescribing partnership” (Figure 5). Patients
should expect that the health care
professionals responsible for their care will
communicate directly with them as well as 
with each other (94). In broad terms, the
prescribing process involves the prescriber 
in deciding whether any particular medication
or combination of medications is indicated.
Whenever feasible, the expected benefits 
and possible risks should be discussed with 
the patient, following which the appropriate
dose and duration of the chosen medication
should be prescribed, dispensed and then
administered to the correct patient. 
Figure 5. The prescribing partnership
Source: Adapted, with the permission of the publisher, from Routledge (94).
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Text in color is specific to the respective medication use process
Errors most commonly occur during the
administration step of the medication use
process, but can occur at any time, including:
storage, prescription, preparation, dispensing
and monitoring (95).
Poor prescribing has been described to take
three forms (96):
• Overprescribing occurs when a medication 
is prescribed whose risk of harm exceeds its
likely benefit (overall or relative to another
medication) in a particular individual. Thus,
every prescription requires the exercise of
good prescribing skills to assess individual
risk–benefit.
• Underprescribing occurs when a medication
is not prescribed whose likely benefit greatly
exceeds the risk of harm. The acquisition 
of sound therapeutic knowledge and skills 
by the prescriber is the key to minimizing 
this risk.
• Misprescribing occurs when either the wrong
medication is prescribed or the wrong dose,
route, frequency or duration of administration
is chosen. It may occur as part of a
medication error.
All of these forms of potentially inappropriate
prescribing can contribute to an unfavourable
risk–benefit ratio, and reduce, or even negate,
the benefits of these medications to the patient.
Poor medication adherence (see Annex 1) may
also result in failure to benefit from the
prescribed medication. However, avoidance 
of harm is only one aspect of appropriate
prescribing. It is important that the right
medicine reaches the right patient. In addition,
significant health care costs can be avoided 
by using medicines more appropriately, thus
achieving better and more cost-effective health
care. These aspects of care are highlighted 
in two informative WHO publications. The first –
The pursuit of the responsible use of
medicines: sharing and learning from country
experiences – highlights examples of how
certain countries have positively addressed
specific important areas of prescribing (97). 
The second – Guide to good prescribing: a
practical manual – is a learning resource which
uses case scenarios to outline the principles 
of selection of first-line medications, followed
by a step-by-step overview of the process 
of rational treatment (98).
Several studies indicate that training,
experience and practice help to reduce
prescribing errors by hospital doctors (99, 100).
However, there is no room for error during
prescribing and thus it is important to train
future doctors in the science of prudent
prescribing, as rightly highlighted by Woods
(101). This is so that prescribers are competent
to provide accurate and appropriate
prescriptions upon graduation. This approach
may also be adopted in relation to non-medical
prescribers in countries where it is applicable.
Health care professionals are also involved in
ensuring safe storage, preparation, dispensing,
administration and monitoring of medications.
These different steps of the medication use
process are no longer the sole domain of any
single health care professional group. However,
it is vital that there is good communication
between different groups of health care
professionals. Interprofessional educational
initiatives may help health care professionals to
learn to work better together in multidisciplinary
teams to promote patient safety. Certainly
communication problems within and between
health care professionals, and between them
and their patients, are often major factors
predisposing to prescribing errors (100), as 
well as other errors involving dispensing and
administration.
Resource-limited settings are often
characterized by a lack of electronic support
systems for prescribing or dispensing,
overcrowding of patients, staff shortages and
inadequate monitoring. In such circumstances
poor prescribing practices, such as the use of
error-prone abbreviations, increase the risk of
medication errors.
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Different health care professionals may elicit
different information about a patient’s
medication history. The optimal medication
histories are often achieved through proper
training of workforce and use of appropriate
tools. In one study in an emergency
department, physicians omitted medicines 
or doses more often in comparison with their
pharmacist colleagues, probably because 
the latter used a structured form to collect 
the information (102). Differences in obtaining 
a medication history may also occur between
specialties within a single health care
profession. In one study, hospitalized patients,
over 65 years of age, being treated by internal
physicians were more likely to receive
neuroleptic agents for long-term hypnotic 
use than those treated by geriatricians (103).
3.2 Patients 
It is well known that adverse drug events occur
most often at the extremes of life (in the very
young and in older people). In older people, 
it is the group of frail patients who are likely 
to be receiving several medications
concomitantly, adding to the risk of adverse
drug events. In addition, the harm of some 
of these medication combinations may
sometimes be synergistic and be greater than
the sum of the risks of harm of the individual
agents. In neonates (particularly premature
neonates), elimination routes through the
kidney or liver may not be fully developed (104).
In children as well as in older persons, the
impact of any resulting harm may be much
more serious. The very young and those of old
age are also less likely to tolerate adverse drug
reactions, either because their homeostatic
mechanisms are not yet fully developed (e.g. 
in the young, especially neonates and infants)
or may have deteriorated (e.g. in older people).
Therefore it is likely that outcomes involving
high-risk (high-alert) medications will be more
severe in these groups.
Medication errors in children, where doses may
have to be calculated in relation to body weight
or age, are a source of major concern.
Prescribing errors resulting from
miscalculations have been reported in a
paediatric intensive care setting (105). In the
PRACtICe study in primary care, the risk of
medication errors was greater in those below
the age of 15 years and in those aged over 64
years (40).
Age also appears to be a major predictor of the
risk of medication errors among older people.
In a study of more than 1400 adult inpatients,
26% of whom experienced at least one
clinically significant medication error; age and
the number of prescribed medications were the
two major predictors of the risk of experiencing
a medication error (106). Sears et al. showed
that self-reported medication errors were more
likely in females than males (107).
Polypharmacy
The number of prescribed medications 
was the second major factor predicting risk 
of experiencing a medication error in adult
inpatients (106). The risk of medication
(prescribing or monitoring) errors in the
PRACtICe study was related to the number of
unique medication items prescribed, reinforcing
the important contribution of polypharmacy 
to the increased risk of harm (40).
Multimorbidity
Multimorbidity (see Annex 1) is becoming 
more prevalent as life expectancy increases 
in many countries around the world. 
A meta-analysis that included 75 studies 
from primary care demonstrated that mental-
physical multimorbidity was associated with 
an increased risk for “active patient safety
incidents” and prescribing errors (108). 
High-risk medical conditions
Certain medical conditions predispose patients
to an increased risk of adverse drug reactions,
particularly renal or hepatic dysfunction and
cardiac failure (where both kidney and liver 
can be compromised together). In part this 
is because the liver and kidney are the two
main organs involved in the metabolism and
excretion of medications from the body, so 
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if the normal doses of a certain medication are
used during liver or kidney failure, dose-related
ADRs (type A reactions) may occur. Hepatic
and renal diseases are often also chronic
conditions in which polypharmacy is common,
and this can predispose patients to drug–drug
interactions or drug–disease interactions. Other
conditions that predispose people to a high risk
of medication-related harm include pregnancy
and poor hydration status (98).
Medication errors may lead to significant harm
in patients with renal disease. In a study 
of 200 renal transplant recipients, clinically
significant medication errors (defined as 
those that contribute to hospital admission)
were associated with more post-transplant
readmissions, significantly higher costs for
those readmissions, overall length of stay, 
and risk of graft failure (109).
In a study of 50 people with liver disease (in 
this case cirrhosis), 27 (54%) had one or more
discrepancies between what the patient
reported they were taking and their medical
record. These discrepancies were more
common in older patients, those who were 
on five or more conventional medications, 
or those having a low to medium adherence
ranking. Concordance between the two lists
was lowest for respiratory medicines (0%), 
and complementary and alternative medicines
(14.5%) (110).
3.3 Strategies to reduce medication
errors related to provider and
patient factors
Health care professionals
James Reason has noted that there should be
a systems approach to counter the effects 
of human fallibility. This approach concentrates 
on the conditions under which people work 
and endeavours to build the defences required
to avert errors or limit their effects (93). The
Clinical Human Factors Group has identified
four major themes – design, teamwork, 
incident investigations, and working in the real
world – that are important components of 
a resilient systems approach to safety, and
these can be usefully applied to medication
safety (111).
Education
The importance of safe medication practice
should be conveyed at an early stage in training
of health care professionals, and embedded 
in training curricula. WHO has developed a set
of evaluation tools designed to complement 
the WHO Patient safety curriculum guide 
for medical schools, published in 2009 (112).
Within the first two years of its circulation, 
the guide had been implemented in curricula
around the world. A multiprofessional version 
of the guide was subsequently produced in
2011 for students of dentistry, medicine,
midwifery, nursing and pharmacy (113).
As more groups of health care professionals
are embracing the role of prescribers, they
should be made aware of the importance 
of establishing an accurate medication history,
covering both prescribed (conventional 
and/or traditional and complementary
medicines) and non-prescribed medications
(including self-prescribed, over-the-counter,
food supplements, and traditional and
complementary medicines). Similarly, a history 
of allergy to any previous medication should be
elicited. Interprofessional education in this 
area can be used to improve communication
within different professional teams. 
Core prescribing competencies are relevant 
to all the prescribing health care professionals
who are faced with addressing the increasing
burden of complex polypharmacy among
people with multimorbidity (114). Several
studies have shown that training using the
WHO Guide to good prescribing (98) was
associated with increased prescribing
competency in a wide range of settings (115).
In the United Kingdom, a prescribing safety
assessment has to be passed to ensure that 
all new medical prescribers, whether trained 
in the United Kingdom or elsewhere, meet 
a similar basic prescribing standard before 
they begin clinical practice (116).
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Prescribing, dispensing, administration and
monitoring of medicines should be the subject
of audit and clinical review by health care
professionals, and consideration may be given
to those using resources emphasizing
medication safety as part of clinical revalidation
or relicensing.
Medication reconciliation
Prescribing errors often occur at transitions 
of care. Pharmacy-led medication reconciliation
on hospital admission may also have economic
benefits (117).
Patients
Many of the patient factors discussed earlier
(e.g. age, multimorbidity) are relatively static.
Patients should be supported by an effective
prescribing team working in close partnership
to ensure they are aware of the purpose of all
medications taken, their likely benefits and
potential risks (94). Useful aide-memoire tools
for patients are available, such as 5 questions
to ask about your medications when you see
your doctor, nurse, or pharmacist (118) and
5 Moments for Medication Safety (119):
The 5 Moments for Medication Safety is a
patient engagement tool developed to support
implementation of the third WHO Global Patient
Safety Challenge: Medication Without Harm. 
It focuses on 5 key moments in the medication
use process, where action by the patient, 
family member or caregiver can greatly reduce
the risk of harm associated with the use of
medications. The five moments are: starting 
a medication, taking my medication, adding 
a medication, reviewing my medication and
stopping my medication. Each moment, in turn,
includes 5 critical questions, some of them
being self-reflective for the patient and some
requiring support from a health professional 
to be answered and reflected upon correctly
(119). Application of the 5 Moments for
Medication Safety tool may vary depending on
the country or local context and specific
setting. It may be applied in targeted population
groups (for example, older people, children,
pregnant and breastfeeding women) or 
in targeted patient groups (for example,
patients with chronic conditions, cancer 
or mental health conditions).
It is important to highlight that principles of 
co-production of resources and partnership
with patients and caregivers should be applied
in relation to developing systems for all the
guidance for high-risk (high-alert) medications
discussed earlier. Medication Safety, Standard
4, developed by the Australian Commission 
on Safety and Quality in Health Care states 
that the patient should be provided with
patient-specific medication information 
that includes treatment options, benefits 
and associated risks (50). The format of the
information provided should meet the needs 
of patients and caregivers while being easily
understandable. Finally, the medication plan
should be discussed with the patient and 
the patient should agree to follow that plan,
with the emphasis on joint decision-making.
Limited language proficiency, lower levels 
of education and misperceptions of illness
severity are more likely to lead to patients
having reduced knowledge regarding their
prescribed medications (120). It is also
important to recognize the particular needs 
of people with intellectual disabilities, including
(but not only) in the hospital (121). Caregivers
also have an important role and can make
similar errors to those made by professionals
(122).
4.1 Systems factors influencing
medication safety
The external environment is an important
determinant of the risk of medication errors.
Prescribing error rates reported in two large
studies were higher in hospitalized patients
(100) than in the community (39). Damen et al.
highlighted the particular concern that adverse
drug events during hospitalization remain
common despite concerted attempts to reduce
them. They also showed that anticoagulant-
related adverse events still occurred during
hospitalization, despite mostly being
preventable, since they were often related 
to dosage errors (39).
The environment in hospitals can contribute 
to error-provoking conditions. The clinical ward
may be busy or understaffed, contributing to
inadequate supervision or failure to remember
to check important information. Interruptions
during critical processes (e.g. administration 
of medicines) can also occur, which can have
significant implications for patient safety (123).
Tiredness and the need to multitask when busy
or flustered can also contribute to error.
Problems may be compounded by poor chart
design (100).
Even within the hospital environment, certain
specialties seem to be associated with particular
risk of medication administration error. In a
prospective observational study, anaesthesia-
trained staff observed randomly selected
operations at a large tertiary care academic
medical centre and identified a rate of medication
errors and/or adverse drug events of 5.3% (124).
Administration errors are a particular problem 
in the anaesthesia setting. In a prospective
incident monitoring study conducted at a large
tertiary hospital in China, the frequency of
administration error was 1.1% based on total
forms returned. The largest categories of error
were omissions, incorrect doses and
substitutions. Significantly more respondents
who had not been able to have sufficient rest
reported inattention as a contributing factor to
error than those who were sufficiently rested
(125).
It is important to note that most prescribing
occurs in primary rather than secondary care. 
A WHO monograph, Medication errors:
technical series on safer primary care, has
highlighted the scale of this problem and
proposes measures to address the issue. This
monograph additionally outlines the particular
issues related to prescribing in children in the
community and in elderly care homes (126).
4.2 Strategies to reduce medication
errors related to systems factors 
Workflow interruptions, noise and busy working
environments can be distracting when
prescribing, dispensing, preparing and/or
administering medication. Tabards have been
worn to reduce interruptions during prescribing
or administering medications, but the evidence
for their value is mixed (127).
Preparing and administering intravenous
medications is particularly error prone.
Systems factors
(work environment) 4
29MEDICATION SAFETY IN HIGH-RISK SITUATIONS
30 MEDICATION SAFETY IN HIGH-RISK SITUATIONS
Checking at each stage markedly reduces 
the probability of error. In the study by
McDowell et al. errors were found most likely 
to occur in the reconstitution step. The
provision of pre-prepared injections removes
the need for reconstitution and may reduce 
the overall error rate significantly (128).
The issue of chart design has been discussed
earlier and there is evidence that such
standardization reduced prescribing errors in
Australia (52, 53). Electronic prescribing may
reduce the rate of prescribing errors (129, 130)
and, in one study, completely eliminated
illegible prescriptions (130). However, the
transition to electronic prescribing is difficult in
resource-limited settings, partly because of the
acquisition and maintenance costs, and hence
paper-based systems are still widely used.
Because prescribing each medication requires
a risk–benefit assessment for each patient, 
it is important that prescribers have access 
to high-quality prescribing advice (e.g. from 
an authoritative formulary) at the time of
prescribing. Prescribing assessment tools can
also be helpful. Building on the original Beers
Criteria (for potentially inappropriate medication
use in older adults), the STOPP criteria have
been developed to highlight potentially
inappropriate medications (see Annex 1), and
the Screening Tool to Alert Doctors to Right
Treatment (START) criteria to highlight
potentially beneficial treatments in older people
(47, 131, 132). Version 2 of this approach now
contains 114 criteria to improve medication
appropriateness, and there is emerging
evidence that appropriate prescribing can
reduce the incidence of falls in older residents
of nursing homes (133).
A set of 41 prescribing appropriateness criteria
was developed for older people in Australia
using the RAND/UCLA appropriateness
method. The criteria could assist in improving
patient care in a variety of settings by
identifying medication problems related to
common medical conditions and frequently
used medications (134).
Tables or software giving information on
drug–drug interactions, and interactions with
traditional and complementary medication are
also helpful, particularly in situations where
polypharmacy is common. These tools can
assist health care professionals to better
address problems related to complex
polypharmacy and reduce risk to patients.
Each country participating in the third WHO
Global Patient Safety Challenge: Medication
Without Harm is urged to take early priority
action to improve medication safety in high-risk
situations and reduce harm by (5):
• identifying its objectives by convening a
group of technical experts, physicians,
nurses, pharmacists, patients, regulators, and
health system leaders to select and prioritize
a small number of high-risk (high-alert)
medications and high-risk situations for
action that are applicable to their situation
and achievable with the resources available;
• developing a plan to achieve those
objectives, including the processes, systems,
patient involvement and education and
training of health care professionals needed
to deliver them;
• developing a range of sustainable strategies
of proven efficacy to address each of the
priority areas in medication safety identified
by the country, as medication errors are often
caused by a combination of medication,
provider and patient, and systems factors;
• developing a strong safety culture within
health care;
• promoting and supporting the establishment
of systems for reporting medication errors at
national and institutional level.
Implications for countries 5
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Annex 1. Glossary 
















Any injury resulting from medical interventions related to a drug. This includes
both adverse drug reactions in which no error occurred and complications
resulting from medication errors (1)
A response to a drug which is noxious and unintended and that occurs at doses
used in humans for prophylaxis, diagnosis or therapy of diseases, or for the
modification of physiological function (2). These are often classified as two types:
Type A and Type B (3)
Type A adverse drug reaction
An augmented pharmacologically predictable reaction which is dose
dependent. It is generally associated with high morbidity and low mortality (4)
Type B adverse drug reaction
A bizarre reaction which is unpredictable pharmacologically and is independent 
of dose. It is generally associated with low morbidity and high mortality (4)
A severe, life-threatening systemic hypersensitivity reaction characterized by
being rapid in onset with potentially life-threatening airway, breathing, or
circulatory problems and is usually, although not always, associated with skin 
and mucosal changes (5)
A medication history obtained by a clinician which includes a thorough history 
of all regular medication use (prescribed and non-prescribed), using a number 
of different sources of information (6)
The process of tapering, stopping, discontinuing, or withdrawing drugs, with 
the goal of managing polypharmacy and improving outcomes (7)
Essential medicines are those that satisfy the priority health care needs of the
population (8)
An aspect of a design that prevents the user from taking an action without
consciously considering information relevant to that action. It forces conscious
attention upon something (“bringing to consciousness”) and thus deliberately
disrupts the efficient or automatized performance of a task (9)
A list of medicines, usually by their generic names, and indications for their use. 
A formulary is intended to include a sufficient range of medicines to enable
medical practitioners, dentists and, as appropriate, other practitioners to prescribe
all medically appropriate treatment for all reasonably common illnesses (10)
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Drugs that bear a heightened risk of causing significant patient harm when they
are used in error. Although mistakes may or may not be more common with these
medications, the consequences of an error are clearly more devastating to
patients (11)
The degree to which use of medication by the patient corresponds with the
prescribed regimen (12)
Any difference between the medication use history and the admission medication
orders (13). Discrepancies may be intentional, undocumented intentional or
unintentional discrepancies (6)
Any preventable event that may cause or lead to inappropriate medication use or
patient harm while the medication is in the control of the health care professional,
patient, or consumer (14)
The formal process in which health care professionals partner with patients to
ensure accurate and complete medication information transfer at interfaces of
care (6)
Patient harm related to medication. It includes preventable adverse drug events
(e.g. due to a medication error or accidental or intentional misuse) and non-
preventable adverse drug events (e.g. an adverse drug reaction)
A structured evaluation of patient’s medicines with the aim of optimizing
medicines use and improving health outcomes. This entails detecting drug related
problems and recommending interventions (15)
Freedom from accidental injury during the course of medication use; activities to
avoid, prevent, or correct adverse drug events which may result from the use of
medications (16)
The multistep process in the use of medications by or for patients, including:
prescribing, ordering, storage, dispensing, preparation, administration and/or
monitoring
Ensuring that the right patients get the right choice of medicine, at the right time.
By focusing on patients and their experiences, the goal is to help patients to (a)
improve their outcomes; (b) take their medicines correctly; (c) avoid taking
unnecessary medicines; (d) reduce wastage of medicines; and (e) improve
medicines safety (17)
The presence of two or more long-term health conditions, which can include (a)
defined physical and mental health conditions such as diabetes or schizophrenia;
(b) ongoing conditions such as learning disability; (c) symptom complexes such as
frailty or chronic pain; (d) sensory impairment such as sight or hearing loss; and
(e) alcohol and substance misuse (18)
An incident that did not reach the patient (19)
The absence of preventable harm to a patient and reduction of risk of
unnecessary harm associated with health care to an acceptable minimum. An
acceptable minimum refers to the collective notions of given current knowledge,
resources available and the context in which care was delivered weighed against
the risk of non-treatment or other treatment (20)
Science and activities relating to the detection, assessment, understanding and
prevention of adverse effects or any other drug-related problem (2)
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Polypharmacy is the concurrent use of multiple medications. Although there
is no standard definition, polypharmacy is often defined as the routine use 
of five or more medications (21). This includes over-the-counter, prescription
and/or traditional and complementary medicines used by a patient
Medications with ineffectiveness or high risk–benefit ratio for a particular
individual or group of individuals (22)
The reduction of risk of unnecessary harm to an acceptable minimum (19)
A known effect, other than that primarily intended, related to the
pharmacological properties of a medication (19)
The various points where a patient moves to, or returns from, a particular
physical location or makes contact with a health care professional for the
purposes of receiving health care (23)
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WHO Envoy for Patient Safety 
World Health Organization 
Geneva, Switzerland 
Edward KELLEY 
World Health Organization 
Geneva, Switzerland
Suzanne HILL
World Health Organization 
Geneva, Switzerland
Neelam DHINGRA-KUMAR
World Health Organization 
Geneva, Switzerland
Sarah GARNER




All Wales Therapeutics and Toxicology Centre










World Health Organization 
Geneva, Switzerland
Mei Lee TAN








World Health Organization Regional Office 

















World Health Organization Regional Office 
for the Western Pacific
Manila, Philippines
Neville BOARD
Australian Commission on Safety and Quality 
in Health Care
Sydney, Australia
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Josè Luis CASTRO
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Organization Regional Office for the Americas








Institute for Safe Medication Practices
Horsham, United States of America
Anita DONLEY
Plymouth Hospitals NHS Trust
Plymouth, United Kingdom of Great Britain 
and Northern Ireland
Frank FEDERICO
Institute for Healthcare Improvement 
Cambridge, United States of America
Albert FIGUERAS






Pan American Health Organization/World Health
Organization Regional Office for the Americas





Institute for Safe Medication Practices Canada
Toronto, Canada
Helen HASKELL
Mothers Against Medical Error
Columbia, United States of America
Jamie HAYES
All Wales Therapeutics & Toxicology Centre
Cardiff, United Kingdom of Great Britain 
and Northern Ireland
Katherine HAYES
World Health Organization 
Geneva, Switzerland 
Elzerie de JAGER
James Cook University 
Townsville, Australia
Regina N. M. KAMOGA
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Regional Medicines Optimisation Innovation
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The University of Edinburgh
Edinburgh, United Kingdom of Great Britain 
and Northern Ireland
Paulo SOUSA







Swansea, United Kingdom of Great Britain 
and Northern Ireland
David U
Institute for Safe Medication Practices Canada
Toronto, Canada
Afam Kanayo UDEOZO






Patricia VAN DEN BEMT














International Federation of Pharmaceutical
Manufacturers and Associations
Geneva, Switzerland 
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For more information, please contact the following departments
Service Delivery and Safety
World Health Organization
Avenue Appia 20 
CH-1211 Geneva 27 Switzerland
Email: patientsafety@who.int
www.who.int/patientsafety
Essential Medicines and Health Products
World Health Organization
Avenue Appia 20 
CH-1211 Geneva 27 Switzerland
Email: empinfo@who.int
www.who.int/medicines
